{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9"},{"groupId":"OG001","value":"9.2"},{"groupId":"OG002","value":"8.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"229"},{"groupId":"OG002","value":"227"}],"units":"Participants"}],"description":"SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Participant's Global Assessment of Disease Activity using VAS centimeters (cm), and Physician's Global Assessment of Disease Activity using VAS (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. An index-based definition of remission occurs with an SDAI score ≤3.3.","groups":[{"description":"Placebo administered orally (PO) once daily (QD) through Week 24.\n\nParticipants continued to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study.","id":"OG000","title":"Placebo"},{"description":"Baricitinib 2 mg PO QD through week 24.\n\nParticipants will continued to take background cDMARD therapy throughout study.","id":"OG001","title":"Baricitinib 2 mg"},{"description":"Baricitinib 4 mg PO QD through week 24.\n\nParticipants continued to take background cDMARD therapy throughout study.","id":"OG002","title":"Baricitinib 4 mg"}],"paramType":"NUMBER","populationDescription":"mITT population: all randomized participants who received at least 1 dose of the study drug. Missing values due to discontinuation of study or drug, rescue, or missing data were imputed using NRI.","reportingStatus":"POSTED","timeFrame":"Week 12","title":"Percentage of Participants Achieving Simplified Disease Activity Index (SDAI) ≤3.3","type":"SECONDARY","unitOfMeasure":"percentage of participants"}